Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203777 | 1.00 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1NPY1RL3MBTL4MBTD1 | |
| SCHEMBL2202799 | 0.88 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1NPY1RL3MBTL4MBTD1 | |
| SCHEMBL2202806 | 0.88 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1NPY1RL3MBTL4MBTD1 | |
| SCHEMBL13973766 | 0.85 | ABCB1 (0.36) | — | |
| SCHEMBL2199721 | 0.84 | MALT1 (0.37) | — | |
| SCHEMBL2199019 | 0.83 | PARP1 (0.35) | MEN1KMT2A | |
| SCHEMBL2199024 | 0.83 | PARP1 (0.35) | MEN1KMT2A | |
| SCHEMBL2198805 | 0.81 | PPP1CA (0.36) | L3MBTL1 | |
| SCHEMBL2201272 | 0.81 | DRD2 (0.38) | CYP2C19MEN1KMT2A | |
| SCHEMBL2198812 | 0.81 | PPP1CA (0.36) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | L3MBTL3 4146/4885L3MBTL1 4149/4885NPY1R 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.